Xiaomi Shares Jump on Europe EV Expansion Plan 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
OpenAI Rejects Apple Trade Secret Theft Claims 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Add as a preferred source on Google
CARLSBAD, Calif., March 07, 2018 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the Company plans to participate in the Cowen 38th Annual Healthcare Conference at the Boston Marriott Copley Place on Wednesday, March 14th, 2018 at 8:00 am ET.
A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.seaspine.com. A replay will remain available on the website for 30 days after the webcast.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact
Lynn Pieper
(415) 937-5402
[email protected]
